Clinical Trials Logo

Filter by:
NCT ID: NCT05591131 Recruiting - Ovarian Cancer Clinical Trials

Genetic Testing in African Americans

GTM-I
Start date: April 20, 2023
Phase: N/A
Study type: Interventional

This is a pilot/feasibility study to conduct genetic testing using tumor/blood samples of African American and Caucasian patients with ovarian and endometrial cancer following surgery at AU Health Medical Center. The aim of the pilot/feasibility study is to sequence a panel of cancer genes on paired tumor/blood (germline) samples of patients with ovarian and endometrial tumors at a two-week time point following surgery at AU Medical Center. While paired testing of tumor and blood (germline) provides direct clinical value to patients, investigators propose to study whether investigators can define and overcome such minority barriers among the Georgia Cancer Center (GCC)/AU Health Medical Center (AUMC) patient population.

NCT ID: NCT05623683 Recruiting - Knee Osteoarthritis Clinical Trials

P4ACE Trial for Persons With Chronic Knee Pain

P4ACE
Start date: April 20, 2023
Phase: N/A
Study type: Interventional

The goal of this single-blind, cross-over clinical trial is to compare the immediate effect of intermittent vs. continuous walking on clinical and mechanistic pain profiles in persons with knee osteoarthritis (OA). In this cross-over trial, participants will perform two types of walking on a treadmill. Intermittent walking will involve 3 blocks of 10 minutes with 2 blocks of 5-minute rest (sitting on a chair) in-between. Continuous walking will involve resting for 10 minutes (sitting in a chair) before walking on the treadmill for 1 continuous block of 30 minutes.

NCT ID: NCT05639556 Recruiting - Cystic Fibrosis Clinical Trials

Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF

Start date: April 20, 2023
Phase:
Study type: Observational

The goal of the study is to examine multiple markers of anthropometrics, body composition, sarcopenia and frailty and compare them to dual energy X-ray absorptiometry (DXA) output, which is considered the current clinical gold-standard tool to measure body composition. The result of this study will provide detailed data regarding the nutrition and body composition within this Cystic Fibrosis population and also provide a baseline evaluation for use of these biomarkers in the future studies including evaluation of nutritional intervention. Further, the study will also include psychosocial and other patient-reported outcomes and medical contributors to understand their contributions to the nutritional failure in the adult advanced lung disease population. Finally, the study will evaluate both established and emerging nutritional and body composition parameters and link them to clinical outcomes in adults with CF across the spectrum of pulmonary function.

NCT ID: NCT05652023 Recruiting - Overactive Bladder Clinical Trials

Noninvasive Ultrasound Assessment of Detrusor Dysfunction

NUADD
Start date: April 20, 2023
Phase:
Study type: Observational

The purpose of this study is to test a new ultrasound method called Quantitative Ultrasound Bladder Vibrometry to detect abnormal bladder function.

NCT ID: NCT05685615 Recruiting - Clinical trials for Ventilator Associated Pneumonia

PK of BV100 in Patients VABP Suspected or Confirmed to be Due to CRAB

Start date: April 20, 2023
Phase: Phase 2
Study type: Interventional

A multicenter Phase 2 study to evaluate the pharmacokinetics, efficacy, and safety of intravenous BV100 combined with Polymyxin B in adult patients with VABP suspected or confirmed to be due to CRAB

NCT ID: NCT05688735 Recruiting - Atopic Dermatitis Clinical Trials

Assessment of the Effect of Coconut and Sunflower Seed Oil Derived Isosorbide Diseters and Colloidial Oatmeal

Start date: April 20, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to compare coconut oil and sunflower seed oil derived isosorbide disesters and colloidal oatmeal, and observe their effect on pediatric atopic dermatitis among males and females aged 2-17.

NCT ID: NCT05689385 Recruiting - Clinical trials for Myocardial Infarction

eHealth-based Cardiac Rehabilitation in Post-myocardial Infarction Patients

Start date: April 20, 2023
Phase: N/A
Study type: Interventional

The goal of this randomized controlled trial is to compare the effect of eHealth-based cardiac rehabilitation with the effect of usual care on exercise capacity and qualify of life in patients after myocardial infarction.

NCT ID: NCT05704738 Recruiting - Atopic Dermatitis Clinical Trials

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)

ROCKET-ASTRO
Start date: April 20, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subjects.

NCT ID: NCT05709574 Recruiting - Clinical trials for Gastric Adenocarcinoma

Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer

Start date: April 20, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to assess the ability of Tadalafil alone and in combination with neoadjuvant FLOT (5-Fluorouracil, Oxaliplatin, and Docetaxel) chemotherapy to suppress myeloid derived suppressor cells (MDSCs) in patients with resectable gastric or gastroesophageal junction adenocarcinoma. Resectable means the tumor may be removed through surgical intervention. Neoadjuvant chemotherapy is chemotherapy received before the primary course of treatment i.e.surgical intervention. The main questions it aims to answer are: - Is Tadalafil treatment with FLOT feasible and safe? - How does tadalafil treatment with FLOT affect the tumor microenvironment (TME)? - Will 8 weeks of neoadjuvant exposure to tadalafil with chemotherapy reduce MDSCs in the TME? Participants will receive Tadalafil for 14 days followed by combination of Tadalafil + FLOT for approximately 8 weeks as a part of standard of care neoadjuvant treatment in the window between cancer diagnosis and surgical intervention to remove their tumor. Tumor tissue, blood, and urine will be collected at the start of the study, after 2 weeks of treatment with Tadalafil alone, and around the time of surgical intervention. Saliva will also be collected at the start of the study.

NCT ID: NCT05769075 Recruiting - Clinical trials for Metastatic Solid Tumor

A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations

Start date: April 20, 2023
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety and tolerability of TY-2136b and to determine the recommended phase 2 dose (RP2D), with dose-escalation stage and dose-expansion stage.